Helminthic infection down-regulates type 1 immune responses in human T cell lymphotropic virus type 1 (HTLV-1) carriers and is more prevalent in HTLV-1 carriers than in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis

Journal of Infectious Diseases

Volumn 191, Issue 4, 2005, Pages 612-618

  Porto, Aurélia F ^a   Santos, Silvane B ^a   Muniz, André L ^a   Basílio, Vanessa ^a   Rodrigues Jr , Waldyr ^a   Neva, Franklin A ^c   Dutra, Walderez O ^b   Gollob, Kenneth J ^b   Jacobson, Steven ^d   Carvalho, Edgar M ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 5;

ANTIGEN EXPRESSION; ARTICLE; CELL ACTIVATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; HELMINTHIASIS; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNE RESPONSE; PREVALENCE; PRIORITY JOURNAL; SCHISTOSOMA MANSONI; SPASTIC PARAPLEGIA; SPINAL CORD DISEASE; STRONGYLOIDES STERCORALIS; T LYMPHOCYTE; VIRUS CARRIER;

ADULT; BRAZIL; CARRIER STATE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; FEMALE; HELMINTHIASIS; HTLV-I INFECTIONS; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-5; MALE; MIDDLE AGED; PARAPARESIS, TROPICAL SPASTIC; SCHISTOSOMIASIS MANSONI; STRONGYLOIDIASIS; VIRAL LOAD;

EID: 13444259780     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/427560     Document Type: Article

References (34)

1. Kramer A, Jacobson S, Reuben JF, et al. Spontaneous lymphocyte proliferation in symptom-free HTLV-I positive Jamaicans. Lancet 1989; 2:923-4.
2. Carvalho EM, Bacellar O, Porto MAF, Santos SB, Galvāo-Castro B, Neva FA. Cytokine profile and immunomodulation in asymptomatic HTLV-1 infected blood donors. J Acquir Immune Defic Syndr 2001; 26:1-6.
3. + T cells in patients with HTLV-1-associated neurological disease. J Virol 2003; 77:9716-22.
4. + CTL clones from patients with HTLV-I-associated neurologic disease secrete proinflammatory cytokines, chemokines, and matrix metalloproteinase. J Immunol 1997; 159:2018-25.
5. + T cells infected with human T-cell lymphotropic virus type I (HTLV-I) is prevented by cytotoxic T lymphocytes. Blood 2000; 95:1386-92.
6. + lymphocytes directly in peripheral blood of HTLV-I-associated myelopathy/tropical spastic paraparesis patients by intracellular cytokine detection. J Immunol 1998; 161:482-8.
7. Nishimoto N, Yoshizaki K, Eiraku N, et al. Elevated levels of interleukin-6 in serum and cerebrospinal fluid of HTLV-I-associated myelopathy/tropical spastic paraparesis. J Neurol Sci 1990; 97:183-93.
8. Osame M. Pathological mechanisms of human T-cell lymphotropic virus type I-associated myelopathy (HAM/TSP). J Neurovirol 2002; 8:359-64.
9. Nagai M, Jacobson S. Immunopathogenesis of human T cell lymphotropic virus type I-associated myelopathy. Curr Opin Neurol 2001; 14:381-6.
10. Araujo MI, de Jesus AR, Bacellar O, Sabin E, Pearce E, Carvalho EM. Evidence of a T helper type 2 activation in human schistosomiasis. Eur J Immunol 1996; 26:1399-403.
11. Finkelman FD, Donohue TS, Goldhill J. Cytokine regulation of host defense against parasitic gastrointestinal nematodes. Annu Rev Immunol 1997; 15:505-33.
12. Fiorentino D, Zlotnik F, Mosmann TR. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991; 147:3815-21.
13. Chomarat P, Rissoan MC, Banchereau J, Mossec P. IFN-γ inhibits IL-10 production by monocytes. J Exp Med 1993; 177:523.
14. Robinson RD, Lindo JF, Neva FA, et al. Immunoepidemiologic studies of Strongyloides stercoralis and human T lymphotropic virus type I infections in Jamaica. J Infect Dis 1994; 169:692-6.
15. Plumelle Y, Edouard A. Strongyloides stercoralis in T-cell leukemia/lymphoma in adults and acquired immunodeficiency syndrome [in French]. Ser Med Interne 1996; 17:125-9.
16. Hayashi J, Kishihara Y, Yoshimura E, et al. Correlation between human T cell lymphotropic virus type-1 and Strongyloides stercoralis infections and serum immunoglobulin E responses in residents of Okinawa, Japan. Am J Trop Med Hyg 1997; 56:71-5.
17. Porto MA, Muniz A, Oliveira J Jr, Carvalho EM. Clinical and immunological consequences of the association between HTLV-1 and strongyloidiasis [in Portuguese]. Rev Soc Bras Med Trop 2002; 35:641-9.
18. Newton RC, Limpuangthip P, Greenberg S, Gam A, Neva F. Strongyloides stercoralis hyperinfection in a carrier of HTLV-I virus with evidence of selective immunosuppression. Am J Med 1992; 92:202-7.
19. Patey O, Gessain A, Breuil J, et al. Seven years of recurrent severe strongyloidiasis in an HTLV-I-infected man who developed adult T-cell leukaemia. AIDS 1992; 6:575-9.
20. Adedayo AO, Grell GA, Bellot P. Case study: fatal strongyloidiasis associated with human T-cell lymphotropic virus type 1 infection. Am J Trop Med Hyg 2001; 65:650-1.
21. Cooke A, Tonks P, Jones FM, et al. Infection with Schistosoma mansoni prevents insulin dependent diabetes mellitus in non-obese diabetic mice. Parasite Immunol 1999; 21:169-76.
22. La Flamme AC, Ruddenklau K, Backstrom BT. Schistosomiasis decreases central nervous system inflammation and alters the progression of experimental autoimmune encephalomyelitis. Infect Immun 2003; 71:4996-5004.
23. Izumo S, Goto I, Itoyama Y, et al. Interferon-alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double-blind, controlled trial. Neurology 1996; 46:1016-21.
24. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33:1444-52.
25. Nagai M, Usuku K, Matsumoto W, et al. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol 1998; 4:586-93.
26. Santos SB, Porto AF, Muniz AL, et al. Exacerbated inflammatory cellular immune response characteristics of HAM/TSP is observed in a large proportion of HTLV-1 asymptomatic carriers. BMC Infect Dis 2004; 4:1-7.
27. Porto AF, Santos SB, Alcântara L, et al. HTLV-1 modifies the clinical and immunological response to schistosomiasis. Clin Exp Immunol 2004; 137:424-9.
28. Neva FA, Oliveira J, Gam AA. Interferon-γ and interleukin-4 responses in relation to serum IgE levels in persons infected with human T lymphotropic virus type I and Strongyloides stercoralis. J Infect Dis 1998; 178:1856-9.
29. Porto MAF, Neva FA, Lisboa W, Thompson R, Alcântara L, Carvalho EM. HTLV-1 decreases Th2 type of immune response in patients with strongyloidiasis. Parasite Immunol 2001; 23:503-7.
30. Gabet AS, Mortreux F, Talarmin A, et al. High circulating proviral load with oligoclonal expansion of HTLV-1 bearing T cells in HTLV-1 carriers with strongyloidiasis. Oncogene 2000; 19:4954-60.
31. Holsberg P. Mechanisms of T-cell activation by human T-cell lymphotropic virus type I. Microbiol Mol Biol Rev 1999; 63:308-33.
32. Agape P, Copin MC, Cavrois M, et al. Implication of HTLV-I infection, strongyloidiasis, and P53 overexpression in the development, response to treatment, and evolution of non-Hodgkin's lymphomas in an endemic area (Martinique, French West Indies). J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20:394-402.
33. Shikiya K, Zaha O, Niimura S, et al. Clinical study on ivermectin against 125 strongyloidiasis patients. Kansenshogaku Zasshi 1994; 68:13-20.
34. Sato Y, Toma H, Sato Y, et al. Reduced efficacy of treatment of strongyloidiasis in HTLV-1 carriers related to enhanced expression of IFN-γ and TGF-β1. Clin Exp Immunol 2002; 127:354-9.